Wednesday, August 26, 2009

NIH/CDC SBIR Solicitation Issued

NIH and CDC issued SBIR Solicitation (PHS 2020-1) inviting small business concerns to submit research proposals. The objective of the SBIR program is to stimulate technology innovation in the private sector, strengthen the role of small businesses to meet Federal R&D needs, and to increase private sector innovation commercialization.

Some of the NIH topics listed for research and new technologies include:

• National Cancer Institute—Biopsy instruments and devices, POC analysis for circulating tumor cells, data harmonization and advanced computation of population health data, plus biosensors for early cancer detection

• National Institute on Drug Abuse—Technologies to integrate data from prescription monitoring programs to current clinical practices, innovative techniques and tools to use for clinical trial participants, handheld devices to support recovery, innovative technologies to support research in drug abuse, and web-based cognitive and neuropsychological testing for substance abuse

• National Heart, Lung and Blood Institute—Innovative tools, techniques and software needed for screening, recruitment, and follow-up of participants in pediatric research

Some of the CDC topics include:

• National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention—A novel technology to identify early infections, a database for storage and data mining, software to perform large scale analyses of infections caused by hepatitis viruses, and decision support tools to use with the Electronic Health Record

• National Center for Immunization and Respiratory Diseases—Technology needed for vaccination delivery and immunization programs

• Coordinating Office for Terrorism Preparedness and Emergency Response—Computer-based models to evaluate strategies and outcomes in pandemic preparedness along with technologies for rapid and efficient communication in emergency response

The due date for proposals is November 9, 2009. For more details, go to, and for general questions, contact Jo Anne Goodnight at